COMPLETE SOLUTIONS VERIFIED GRADED A+
2026/2027
PDC calculation PDC = (# of unique days with
supply / number of days in a period)
x 100
Which medication is a Jak inhibitor? d. Xeljanz (tofacitinib)
a. Humira (adalimumab)
b. Orencia (abatacept)
c. Actemra (toclizumab)
d. Xeljanz (tofacitinib)
Which medication can elevate a. Actemra (toclizumab)
cholesterol?
a. Actemra (toclizumab)
b. Enbrel (etanercept)
c. Simponi (golimumab)
d. Kineret (anakinra)
Which shingles vaccine is safe to c. Shingrix
administer with TNF inhibitors?
a. Adacel
b. Zostavax
c. Shingrix
,d. Varivax
Most biologics increase the risk b. Taltz (ixekizumab)
of infections, which of the
following also increases the risk
of
neutropenia?
a. Rituxin (rituximab)
b. Taltz (ixekizumab)
c. Remicade (infliximab)
d. Cimzia (certolizumab pegol)
Which psoriasis medication does b. Otezla (apremilast)
not require screening for
tuberculosis?
a. Stelara (ustekinumab)
b. Otezla (apremilast)
c. Cocentyx (seculinumab)
d. Humira (adalimumab)
What is the standard starting dose b. 160mg subcutaneously once,
for Taltz (ixekizumab) when used to followed by 80mg subcutaneously
treat psoriatic arthritis? every 4 weeks
a. 160mg subcutaneously once,
followed by 80mg subcutaneously at
weeks 2, 4, 6, 8,
10
and 12; then 80mg subcutaneously
,every 4 weeks
b. 160mg subcutaneously once,
followed by 80mg subcutaneously
every 4 weeks
c. 160mg subcutaneously once,
followed by 80mg subcutaneously
every week for 4 weeks,
then 80mg every 4 weeks
d. 160mg subcutaneously once,
followed by 80mg subcutaneously
every other week
A 45 y/o, 200lb patient is d. Dupixent (dupilumab)
struggling with severe dermatitis
and the provider wants to
potentially
start a biologic. Which medication
would you recommend?
a. Protopic (tacrolimus)
b. Humira (adalimumab)
c. Stelara (ustekinumab)
d. Dupixent (dupilumab)
A 56 y/o, 140lb patient with psoriasis a. Inject 45 mg subcutaneously at
will be starting Stelara weeks 0 and 4, followed by 45 mg
(ustekinumab), but the provider every 12 weeks
wants to verify the dosing of the
medication. What starting dose
, would you recommend?
a. Inject 45 mg subcutaneously at
weeks 0 and 4, followed by 45 mg
every 12 weeks
b. Inject 90 mg subcutaneously at
weeks 0 and 4, followed by 90 mg
every 12 weeks
c. Infuse 260 mg IV over at least 1 hour
as a single dose, followed 8 weeks
later with 90 mg
subcutaneously every 8 weeks
d. Infuse 520 mg IV over at least 1
hour as a single dose, followed 8
weeks later with 90 mg
subcutaneously every 8 weeks